Abstract: The present invention provides plant growth-promoting activities of natural plant active constituent calliterpenone and its derivatives belonging to the group phyllocladane diterpenoids. These phytochemicals and derivatives exhibit remarkable growth promoting activities on plant roots, shoots and promote seed germination both in monocotyledonous and dicotyledonous plants. These phytomolecules possess the antagonistic activity against allelochemicals of plant growth retardant nature and hence can be used to alleviate their detrimental effects.

Abstract: Disclosed is a lubricating composition such as a lubricant, a lubricating grease, or a rust preventive oil for use in a torque limiter and a ball-and-roller bearing; the lubricating composition having chemical attack resistance for a synthetic resin molded product. The lubricating composition comprises as a base oil at least one synthetic saturated hydrocarbon oil selected from the group consisting of a poly-&agr;-olefin, and an ethylene-&agr;-olefin copolymer. When a phosphoric acid ester is used as a compounding agent, or at lease one lubricating grease selected from the group consisting of an urea compound, silica powder, and bentonite powder is mixed therein, the lubricating composition is a rust preventive oil using a metal salt of sulfonic acid and the like. The lubricating composition is suitably used for machine parts of a business machine including the synthetic resin molded product.

Abstract: A composition comprises a sulphur- and phosphorus-free, boron-containing overbased metal salt of a calixarene. The boron-containing overbased calixarene is useful in a lubricant additive composition, a lubricant composition, and a method to lubricate an internal combustion engine. The boron-containing overbased calixarene advantageously provides detergent and antiwear performance and does so without increasing the sulphur or phosphorus content of a lubricant additive or lubricant composition.

Abstract: A cutting fluid applicable for the machining of vitreous, crystalline or aggregate materials such as glass, glass-ceramics, ceramics, stone, concrete, silicon and the like. The cutting fluid comprises a solution containing organic molecules—in particular silanes, silanols, and siloxanes—capable of forming covalent bonds with such vitreous, crystalline or aggregate materials. The organic molecules in the cutting fluid is believed to improve the rate of manufacturing productivity, surface finish quality, and decrease the incidence of sub-surface damage caused by particulate adhesion to the cutting or abrading tool during a machining process of these kinds of substrates. The reduced clogging of cutting surfaces and increased lubricity of the cutting fluid may also prolong the useful life of the machining tools when used against these kinds of substrates.

Abstract: Thermally formed thermoplastic articles can be protected from stress cracking in the presence of stress cracking promoting compounds by forming a shaped article comprising a thermoplastic and a liquid hydrocarbon oil composition. We have found that the liquid hydrocarbon oil composition prevents the stress cracking promoting materials from interacting with the polymeric structure of the stressed container to prevent or inhibit stress cracking in such materials. The methods and compositions of the invention are particularly useful in preventing stress cracking in polyethylene terephthalate beverage containers during bottling operations during which the bottle is contacted with aqueous and non-aqueous materials such as cleaners and lubricants that can interact with the polyester to cause stress cracking particularly in the container base.

Abstract: The present invention provides a nonflammable water-based cutting fluid composition which affords excellent dispersion property of abrasives, which does not cause problems involving in flammability upon the use for cutting process of a hard and brittle materials, which can be readily washed, and which can achieve sufficient rust preventive property even if it is used in an equipment for oil use. Provided by the present invention is a nonflammable water-based cutting fluid composition containing a polycarboxylic acid-based polymer compound and/or a salt thereof having a weight-average molecular weight of 1,000-200,000, and additionally a carboxylic acid and/or a salt thereof upon needs for a rust preventive property.

Abstract: Disclosed are personal cleansing compositions, and corresponding methods of application, wherein the compositions comprise (A) a cleansing phase containing a cleansing surfactant and water; and (B) an active phase containing lipophilic carrier and preferably a skin active agent; wherein the cleansing and active phases are physically separated from one another by one or more packaging barriers, located in the same or separate packages. Preferred embodiments are further defined by selected lipophilic carrier rheologies, defined active phase particulates for improved skin feel, and selected chronic skin active agents for use in the active phase. These compositions and corresponding methods provide improved cosmetics, skin feel, and/or skin active efficacy.

Abstract: Multiphase soaps in which the individual phases are highly visible when viewed from above and from the side have high stability. Their use permits various scent experiences to be achieved during the washing operation.

Abstract: Particulate and metal ion contamination is removed from a surface, such as a semiconductor wafer containing copper damascene or dual damascene features, employing aqueous composition comprising a fluoride containing compound; a dicarboxylic acid and/or salt thereof; and a hydroxycarboxylic acid and/or salt thereof.

Abstract: A decarbonization formulation for removing carbon deposits and the like, and method of application therefore. The preferred embodiment of the present invention teaches a method for removing carbon deposits from an internal combustion engine and composition therefore wherein there is utilized a solution comprising water and glycol ether based brake fluid in about a 50/50 ratio. The preferred brake fluid utilized in the present invention is H-121 Premium Plus Brake Fluid by Cooper Industries, Wagner Brake Division of St. Louis, Mo. The solution is chilled to about 40-50 degrees and about one pint is added in liquid form to the air intake with the engine running at about 2000 rpms over a period of about one minute. The concentration, temperature of the fluid, and rate of application can vary depending upon the size and type of engine.

Abstract: The invention relates to a cleaning composition for apparatus for processing thermoplastic melts, which composition essentially comprises discrete particles capable of plastic deformation and made from a thermoplastic (A) with a melting point above 200° C. and with a crystallinity of not more than 50%, and comprises an amorphous or semicrystalline thermoplastic (B) with a processing temperature below the melting point of the thermoplastic (A). The proportion of the thermoplastic (A) is from 1 to 95% by weight and that of the thermoplastic (B) is from 5 to 95% by weight. The total of the percentage proportions by weight of (A) and (B) is always 100% or less.

Abstract: A rinse agent composition is provided. The rinse agent composition includes a sheeting agent for promoting draining of sheets of water from a surface, and a humectant. The humectant is a component which retains at least 5 wt. % water when the humectant has been contained at an equilibrium of 50% relative humidity and room temperature. The sheeting agent and humectant are preferably provided at a ratio of between about 5:1 and about 1:3. A method for rinsing a substrate surface in the presence of high solids containing water is provided. High solids containing water is generally considered to be water having a total dissolved solids content in excess of 200 ppm.

Abstract: An cleaning composition loaded on a cleaning wipe having improved biocidal release from the cleaning wipe. The cleaning composition includes a cationic biocide, a biocide release agent and water. The cationic biocide release agent has an ionic strength in the cleaning composition of at least about 5×10−3 mol/l.

Abstract: A contaminated surface polishing-washing detergent composition comprises a polishing media and a dispersion medium wherein at least a part of the polishing media is made of a fine powder of an RB ceramic and/or CRB ceramic. The composition is effective in polishing-washing the surfaces of a precision-worked base material, and after the polishing-washing, the particles of metal oxides and the particles of removed burrs and the cutting metal chips are simply separated from the composition by use of the difference in specific gravity to re-use it by recycling.

Abstract: The invention relates to a liquid composition comprising dispersed herein solid particles comprising a solid wax matrix, wherein an active is distributed. The invention also relates to particles in the liquid composition and the processes and uses of the composition and the particles.

Abstract: The present invention relates to compositions and methods for improving the visual properties of a wash process which utilizes lipophilic fluid (e.g., siloxane solvent) by coloring agents, sudsing agents and mixtures thereof.

Abstract: A process for preparing a homogeneous, solid cleaning composition that comprises a cleaning agent, and optionally an additive agent and a hardening agent is provided. The compositions are processed in a continuous mixing system at high shear, at or below the melting temperature of the ingredients. Preferably, the ingredients are processed in an extruder, and the mixture is extruded directly into a mold or other packaging system for dispensing the cleaning composition. The consistency of the composition ranges from that of a fused block solid to a malleable article. The cleaning compositions are useful for warewashing and cleaning hard surfaces, rinsing, sanitizing, deodorizing, laundry detergents, conveyor lubricants, and the like.

Abstract: The invention relates to detergent compositions comprising from 10-60 wt % of a surfactant system and having a maximum Residues Index of 25 and a maximum Secondary Residues Index of 15. The detergents claim provide good performance in the wash based on the quantities of detergent components in the compositions.

Abstract: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, compositions having burst indices of 8 or less for systemic applications and systems releasing 10% or less of the total dose of beneficial agent in the first 24 hours after implantation for local applications. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Abstract: Transgene constructs for generating transgenic animals, wherein the transgene encodes a gene product which modulates transcription of a hypertrophy-sensitive gene, are provided. Further provided are recombinant vectors comprising the transgenes of the invention. Further provided are transgenic animals generated using the transgene constructs. Further provided are enzyme-based, cell-based, and whole-animal-based assays for detecting substances having therapeutic activity toward cardiac hypertrophy. Further provided are compositions comprising substances which modulate levels of active product of a hypertrophy-sensitive gene. Further provided are methods of treating cardiac hypertrophy.

Abstract: Disclosed are lanthionine bridged peptides having the structure methods of their preparation and their use as pharmacologically active agents.

Abstract: The invention provides a peptide suitable for the prophylaxis, treatment, diagnosis or monitoring of arthritis. The peptide contains a contiguous sequence element of 9 amino acid residues (nonapeptide), having the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9. In the sequence, X2, X6 and X7 are any amino acid; X1 is any amino acid except K, H, R, E, D; X3 is S or T; X4 is one of F, L, I, V, A, G, C, P; X5 is one of A, G, C, P, S, N, T, V; X8 is one of V, L, I, M; and X9 is E or D. The peptide is also a part of a mammalian cartilage, joint or arthritis-related protein such as collagen or a cartilage protein, and is between 9-20 amino acids in length. Furthermore, the peptide is recognised by freshly isolated T cells from rats in which Adjuvant Arthritis is induced and/or is recognised in vitro by T cell clone A2b.

Abstract: Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of a TRANCE/RANK inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.

Abstract: A novel dipeptide compound inhibiting the enzymatic activity of HIV protease and an anti-AIDS medicine comprising this dipeptide compound as an effective component represented by formula (I) wherein R1, R2, and R3 independently represent C1-4 alkyl, alkoxyl, hydrogen etc . . . (provided that not all of the R1, R2, and R3 are hydrogen), R2 and R3 may form a ring together, R4 represents C1-4 alkyl or hydrogen; X is a methylene group or a sulfur atom; Y represents e.g., a five or six member monocycle or aryloxyalkyl having up to 12 carbon atoms (provided that the aromatic ring may be substituted by alkyl etc . . . ); and Z represents a C1-6 aliphatic hydrocarbon or an aromatic hydrocarbon having up to 12 carbon atoms (provided that this aromatic ring may be substituted by alkyl etc . . . , or at least one carbon atom in the aromatic hydrocarbon may be replaced by a hereto atom).

Abstract: A method is described for treating hypercholesterolemic atherosclerosis or for reducing total cholesterol while raising high-density lipoportoein cholesterol. It involves administering to a patient a substantially pure complex derived from flaxseed and containing secoisolariciresinol diglucoside (SDG), cinnamic acid glucosides and hydroxymethyl glutaric acid.

Abstract: There are described 11-O-substituted macrolides and their descladinose derivatives and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier. Also described is a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for the preparation of such compounds.

Abstract: Ribavirin derivatives represented by formula I wherein at least one of R2, R3 or R5 is a straight or branched chain polyalkylene oxide polymer conjugate, and pharmaceutical compositions containing them as well as their use to treat patients having susceptible viral infections, alone and in combination with a therapeutically effective amount of interferon-alpha are disclosed.

Abstract: A method for delivering an isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of an isolated polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.

Abstract: There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection, using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.

Abstract: A method is described for improving the pharmacokinetics of a drug in a subject, by co-administering oligomers, preferably PMO's (phosphorodiamidate morpholino oligonucleotides), antisense to RNAs encoding drug-metabolizing enzymes, particularly p450 enzymes. The oligomers reduce production of the drug-metabolizing enzymes, which extends drug half-life and effectiveness and/or decreases drug toxicity.

Abstract: The present invention is directed to a method of stimulating ciliary beat frequency to promote mucociliary or cough clearance of retained mucus secretions from the lungs, sinuses, upper airways, ears, eyes, genito-urinary tract, spermatozoa, ovaries, fallopian tubes, neutrophils, and macrophages of a patient. The method comprises administering uridine triphosphates, adenosine triphosphates, cytidine triphosphates, or dinucleoside tetraphosphates and the derivatives thereof to an affected body of a patient, to treat dysfunction of the mucociliary clearance system as a result of impaired ciliary movement in the patient.

Abstract: The present invention relates to novel sulfoxide and bis-sulfoxide compounds, compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Abstract: The present invention provides a compound having sPLA2 inhibiting activity. The compound represented by the formula (I): wherein R1 is (a) C1 to C20 alkyl, C2 to C20 alkenyl, C2 to C20 alkynyl, carbocyclic groups, heterocyclic groups or the like; R2 is CONH2 or CONHNH2; one of R3 and R4 is —(L2)-(acidic group) wherein L2 is a group connecting with an acid group and the length of the connecting groups 1 to 5 atoms, and the other is a hydrogen atom; its prodrug, their pharmaceutically acceptable salt, or solvate thereof.

Abstract: A method of treating SLE symptoms of an SLE patient comprising administering to an SLE patient an amount of vitamin D compound effective to reduce symptoms and observing a reduction in symptoms is disclosed.

Abstract: Novel 17,20-methanofusidic acid derivatives are used in pharmaceutical compositions for the treatment of infections, in particular in topical compositions for the treatment of skin or eye infections.

Abstract: A class of compounds is described which can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula II wherein each of R1, R2, and R3 is independently selected from hydrido, halo, and nitro; wherein R8 is selected from haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted arylalkoxy and optionally substituted aryloxyalkyl; where Y is selected from fluoroalkyl, and wherein R9 alkylamino; or a pharmaceutically-acceptable salt or tautomer thereof.

Abstract: The present invention relates to the use of native hepoxilins and of hepoxilin analogs for the regulation of insulin secretion and to the use of hepoxilin analogs as anti-inflammatory, anti-diabetic and anti-thrombotic compounds.

Abstract: A compound of formula I in which M, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, B5, B6, K1, and K2 are defined herein and are novel effective tryptase-inhibitors.

Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1-C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1-C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded.

Abstract: A class of compounds is described which can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula II: wherein each of R1, R2, and R3 is independently selected from hydrido, halo, and nitro; wherein R8 is selected from haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted arylalkoxy and optionally substituted aryloxyalkyl; wherein Y is selected from fluoroalkyl, and and wherein R9 is alkylamino; or a pharmaceutically-acceptable salt or tautomer thereof.

Abstract: Compounds of formula (I): or a pharmaceutically acceptable salt thereof, or solvate of either entity, wherein R4 is a guanidinyl moiety and the other substituents are as defined in the text, are urokinase inhibitors.

Abstract: The present invention relates to novel indolin-2-one derivatives of formula: to the preparation and to the pharmaceutical compositions comprising them. These compounds have an affinity for oxytocin receptors.

Abstract: Compounds represented by formula I: wherein R2 is H, halogen, NHNH2, (C1-4)alkyl, O(C1-6)alkyl, and haloalkyl; R4 is H or Me; R5 is H or (C1-4)alkyl; R11 is (C1-4)alkyl, (C1-4)alkyl(C3-7)cycloalkyl, or (C3-7)cycloalkyl; and Q is naphthyl, fused phenyl(C4-7)cycloalkyl and fused phenyl-5, 6, or 7-membered saturated heterocycle having one to two heteroatom selected from O, N, or S, said Q being substituted with from 1 to 4 R12 substituents selected from: R13, (C1-6)alkyl, (C3-7)cycloalkyl, or (C2-6)alkenyl, said alkyl, cycloalkyl, or alkenyl being optionally substituted with R13; or a salt thereof. Compounds represented by formula I have inhibitory activity against Wild Type, single and double mutant strains of HIV.

Abstract: Broad-spectrum anti-emetic pharmaceutical compositions are disclosed. The discloses broad-spectrum ant-emetics disclosed herein comprise selected neuroreceptor antagonists specifically formulated to treat and prevent to most common forms of emesis. In one embodiment the ant-emetic compositions include lorazepam, diphenhydramine, promethazine, and metoclopramide. The pharmaceutical compositions include, but are not limited to oral and parenteral forms and may include one or more pharmaceutically acceptable excipient.

Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

Abstract: A substituted aminomethyl-phenyl-cyclohexane derivative of formula I or Ia, and their a diastereomer, enantiomer, or of a salt formed with a physiologically tolerated acid. Also disclosed are method for preparing the substituted aminomethyl-phenyl-cyclohexane derivative, pharmaceutical compositions comprising the same and method of using the same for treating pain, urinary incontinence, itching, diarrhea, inflammatory and allergic reactions, depression, drug or alcohol abuse, gastritis, cardiovascular diseases, respiratory tract diseases, coughing, mental illnesses and epilepsy.

Abstract: The present invention is a pyrimidine, triazine or pyrazine derivative of the formula or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, R4, X, Y and Z are as defined in the specification. The invention is a pharmaceutical composition containing an effective amount of the compound of formula 1, its preparation and to a method of treatment, control or prevention of acute and/or chronic neurological disorders by administering a therapeutically effective amount of a compound of formula 1.

Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1, R2, R3a, R3b, R4, R5, and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Abstract: There is provided a compound represented by the general formula (1): wherein Het represents an optionally substituted heterocyclic group; A1 and A2 each independently represent —CH═, etc.; A3 represents —CH2—, etc.; R1 represents a 4-fluorophenyl group, etc.; R2 represents an alkyl group; n represents 0, 1 or 2, provided that when A1 and A2 both are —CH═, A3 represents —CH2— or —SO2—, which is an indole derivative or a mono- or diazaindole derivative that has COX-2 inhibitory activity and is useful as a pharmaceutical, such as an anti-inflammatory agent, or addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.

Abstract: A purified tyrphostin of a general formula: wherein, for Compound I, R6 is either at position 6 or at position 7, or, for Compound II, R6 is either at position 6 or at position 8.